Trials / Completed
CompletedNCT00203164
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 254 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rasagiline mesylate | rasagiline mesylate 1 mg oral once daily |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2005-07-01
- Completion
- 2006-09-01
- First posted
- 2005-09-20
- Last updated
- 2010-03-09
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00203164. Inclusion in this directory is not an endorsement.